Trulicity 0.75mg Dulaglutide Subcutaneous Injection ATEOS 2 Pens

Trulicity 0.75mg Dulaglutide Subcutaneous Injection ATEOS 2 Pens contains dulaglutide, a glucagon-like peptide-1 receptor agonist, commonly known as a GLP-1 receptor agonist. It is a prescription-only subcutaneous injection medicine intended for use under the supervision of a licensed healthcare professional.

Trulicity is commonly prescribed for blood glucose management in suitable patients with type 2 diabetes, as part of a healthcare professional-directed treatment plan that may include diet, exercise, glucose monitoring, and other medicines when appropriate. It should only be used after medical assessment and according to the prescribed dosing schedule.

This product listing refers to Trulicity 0.75mg ATEOS 2 Pens.

Product Information

• Product Name: Trulicity 0.75mg Dulaglutide Subcutaneous Injection ATEOS 2 Pens
• Japanese Name: トルリシティ皮下注 0.75mg アテオス
• Chinese Name: Trulicity 易週糖0.75mg 度拉糖肽皮下注射液 ATEOS 2支裝
• Active Ingredient: Dulaglutide
• Strength: 0.75mg
• Pack Size: 2 pens
• Dosage Form: Subcutaneous injection pen
• Device Type: ATEOS pen
• Route of Administration: Subcutaneous
• Drug Class: GLP-1 receptor agonist
• Brand Owner: Eli Lilly
• Product Type: Prescription medicine
• Use: Use only as directed by a licensed healthcare professional

What Is Trulicity 0.75mg Dulaglutide Subcutaneous Injection ATEOS?

Trulicity 0.75mg Dulaglutide Subcutaneous Injection ATEOS is a prefilled injection pen containing dulaglutide for subcutaneous administration. Dulaglutide belongs to the GLP-1 receptor agonist class of medicines.

GLP-1 receptor agonists work on pathways involved in insulin secretion, glucagon regulation, gastric emptying, appetite signaling, and blood glucose control. Trulicity may be used in suitable patients with type 2 diabetes as part of a complete diabetes care plan.

This medicine should not be used without a prescription or professional medical supervision.

Key Features

Trulicity 0.75mg Dulaglutide Subcutaneous Injection ATEOS 2 Pens is known for:

• Contains dulaglutide 0.75mg
• ATEOS subcutaneous injection pen format
• Pack contains 2 pens
• GLP-1 receptor agonist medicine
• Commonly used in type 2 diabetes care
• Usually administered once weekly as prescribed
• Manufactured by Eli Lilly
• Prescription-only medicine
• Intended for healthcare professional-directed use

About Dulaglutide

Dulaglutide is a GLP-1 receptor agonist. It acts on GLP-1 receptors involved in blood glucose regulation and metabolic pathways.

Under healthcare professional guidance, dulaglutide may help support:

• Glucose-dependent insulin secretion
• Reduced glucagon secretion when glucose levels are elevated
• Slower gastric emptying
• Blood glucose management
• Glycaemic control as part of a diabetes care plan
• Ongoing metabolic monitoring

Individual suitability, response, and tolerability vary. Your healthcare provider will decide whether Trulicity is appropriate based on your medical history and treatment goals.

Dose Strength Information

The 0.75mg strength is commonly used as a starting dose in Trulicity treatment or as directed by a healthcare professional. A doctor may adjust treatment depending on glycaemic response, tolerability, medical history, and the patient’s overall diabetes management plan.

A healthcare provider may review:

• Type 2 diabetes treatment goals
• Blood glucose monitoring results
• HbA1c levels
• Current medications
• Risk of hypoglycemia
• Kidney function
• Digestive tolerability
• Medical history and contraindications

Patients should not increase, decrease, skip, restart, or stop doses without medical advice.

How to Use Trulicity 0.75mg Dulaglutide Subcutaneous Injection ATEOS

Use exactly as directed by your doctor, pharmacist, or healthcare provider.

General administration guidance may include:

• Inject under the skin as prescribed.
• Common injection areas may include abdomen, thigh, or upper arm.
• Trulicity is usually used once weekly when prescribed.
• Use on the same day each week where possible.
• Do not inject into a vein or muscle.
• Rotate injection sites.
• Do not share injection pens with others.
• Each pen is for single use only.
• Follow the official instructions for use supplied with the medicine.

Always read the patient information leaflet and follow healthcare professional guidance.

Who May Be Prescribed Trulicity 0.75mg Dulaglutide Subcutaneous Injection ATEOS?

Trulicity may be prescribed to suitable adult patients with type 2 diabetes as part of a healthcare professional-supervised treatment plan.

A healthcare professional may assess:

• Type 2 diabetes diagnosis
• HbA1c and blood glucose goals
• Diet and exercise plan
• Current diabetes medicines
• Hypoglycemia risk
• Kidney function
• Gastrointestinal history
• Pancreatitis risk
• Gallbladder disease risk
• Diabetic retinopathy status
• Pregnancy or breastfeeding status
• Ability to safely use an injectable medicine

This product is not suitable for everyone and should only be used after medical assessment.

Important Safety Information

Before using Trulicity 0.75mg Dulaglutide Subcutaneous Injection ATEOS, tell your healthcare provider if you:

• Have type 1 diabetes or diabetic ketoacidosis
• Have a history of pancreatitis
• Have gallbladder problems
• Have severe stomach or intestinal disease
• Have kidney disease
• Have liver disease
• Use insulin or sulfonylurea medicines
• Have diabetic retinopathy
• Have a history of thyroid tumors or endocrine disorders
• Are pregnant, planning pregnancy, or breastfeeding
• Have allergies to dulaglutide or any ingredient in the injection
• Are taking any prescription, over-the-counter, or herbal medicines

Possible Side Effects

Common side effects may include:

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Abdominal pain or discomfort
• Indigestion
• Reduced appetite
• Fatigue
• Injection site reaction

Serious side effects may occur and require medical attention.

Seek medical help immediately if you experience:

• Severe or persistent abdominal pain
• Severe vomiting or dehydration
• Signs of pancreatitis
• Signs of gallbladder problems
• Allergic reaction
• Severe hypoglycemia symptoms, especially if used with insulin or sulfonylurea
• Vision changes
• Neck lump, difficulty swallowing, or persistent hoarseness

Storage

Store according to the product package and pharmacist instructions.

General storage recommendations:

• Keep in original packaging.
• Store refrigerated if required by product instructions.
• Do not freeze.
• Protect from heat and direct sunlight.
• Keep out of reach of children and pets.
• Do not use after the expiry date.
• Dispose of used pens safely according to local guidance.

Important Notes

• Trulicity 0.75mg Dulaglutide Subcutaneous Injection ATEOS 2 Pens is a prescription medicine.
• This listing refers to 2 pens.
• Use only under healthcare professional supervision.
• Do not share injection pens.
• Not intended for type 1 diabetes or diabetic ketoacidosis.
• Dose adjustment should only be made by a healthcare professional.
• It should be used as part of a comprehensive diabetes care plan.
• Individual response and tolerability may vary.
• Trulicity should not be used together with another GLP-1 receptor agonist unless specifically directed by a healthcare professional.

Disclaimer

This product page is for general product information only and does not replace professional medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.

Trulicity is a prescription medicine. Use only under the supervision of a licensed healthcare professional. This product information is for reference only and does not replace medical advice, diagnosis, or treatment.